ABSTRACT
Background and Aims Inflammatory bowel disease is associated with an increased risk of skin cancer. The aims of this study were to determine whether genomic variants associated with IBD susceptibility are also associated with skin cancer susceptibility and if such risk is augmented by the use of immune-suppressive therapy.
Methods The discovery cohort included participants in the UK Biobank (n=408,381). The validation cohort included participants in the Michigan Genomics Initiative (n=51,405). The primary outcome of interest was skin cancer, sub-grouped into non-melanoma (NMSC) and melanoma skin cancers (MSC). Multivariable logistic regression was performed to identify genomic predictors of skin malignancy. Validated SNPs were evaluated for effect modification by immune-suppressive medication.
Results The discovery cohort included 11,079 cases of NMSC and 2,054 cases of MSC. The validation cohort included 7,334 cases of NMSC and 3,304 cases of MSC. Thirty variants were associated with risk of NMSC in the discovery cohort, of which six replicated in the validation cohort [Increased risk: rs7773324-A (DUSP22; IRF4), rs2476601-G (PTPN22), rs1847472-C (BACH2), rs72810983-A (CPEB4); Decreased risk: rs6088765-G (PROCR; MMP24), rs11229555-G (ZFP91-CNTF; GLYAT)]. Twelve variants were associated with risk of MSC in the discovery cohort, of which three replicated in the validation cohort (Increased risk: rs61839660-T (IL2RA); Decreased risk: rs17391694-C (GIPC2; MGC27382), rs6088765-G (PROCR; MMP24)]. No effect modification was observed.
Conclusion The results of this study highlight shared genetic susceptibility across IBD and skin cancer, with increased risk of NMSC in those who carry risk variants in IRF4, PTPN22, CPEB4, and BACH2 and increased risk of MSC in those who carry a risk variant in IL2RA.
Competing Interest Statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Dr. Kahlenberg reports grants from NIH, during the conduct of the study; grants and personal fees from BMS, grants from Janssen, personal fees from AstraZeneca, personal fees from Eli Lilly, personal fees from Ventus Therapeutics, outside the submitted work. Dr. Gudjonsson reports grants from Almirall, Eli Lilly, Kyowa Kirin, BMS/Celgene, personal fees from Eli Lilly, personal fees from Almirall, personal fees from Novartis, personal fees from BMS, personal fees from Astra-Zeneca, personal fees from Boehringer Ingelheim, personal fees from Sanofi, personal fees from Galderma, and personal fees from AnaptysBio, outside of the submitted work. Dr. Higgins reports personal fees from Abbvie, personal fees from Eli Lilly, personal fees from Pfizer, outside the submitted work. All other authors have nothing to disclose.
Funding Statement
KCC reports departmental funds. JMK reports the mentoring award K24-AR076975.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The analyses in this study were conducted through the UK BioBank Resource Project 18120 (awarded to EKS). This study was conducted with approval from the University of Michigan Institutional Review Board (HUM00159951).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of Funding: KCC reports departmental funds. JMK reports the mentoring award K24-AR076975.
Conflicts of Interest: Kelly C. Cushing: None
Xiaomeng Du: None
Yanhua Chen: None
LC Stetson: None
Annapurna Kuppa: None
Vincent L. Chen: None
J. Michelle Kahlenberg: grants from BMS, Jannsen, and Q32 bio, advisory boards for Astrazeneca, Eli Lilly, BMS, Boehringer Ingleheim, Admirex Pharmaceuticals, ProVention Bio, Ventus Therapeutics
Johann E. Gudjonsson: Advisory Board: Eli Lilly, Almirall, Novartis, BMS, Astra-Zeneca, Boehringer Ingelheim, Sanofi, Galderma, AnaptysBio. Research Grants: Almirall, Eli Lilly, Kyowa Kirin, BMS/Celgene.
Peter DR Higgins: Dr. Higgins reports personal fees from Abbvie, personal fees from Eli Lilly, personal fees from Pfizer, outside the submitted work.
Elizabeth Speliotes: None
Data Availability
All results are included in the manuscript.
